検索画面
細胞材料開発室サイト

戻る 戻る
細胞番号 : 細胞名
RCB1130 : TGBC2TKB  update : 2024/08/14
細胞特性(Comment:英)Japanese gallbladder carcinoma from the same patient of TGBC1TKB. Application consideration
細胞特性(日)原発部位より分離された日本人胆嚢癌。TGBC1TKBとは同一患者。培養開始にあたっての注意
細胞特性(寄託者記述:英)
細胞特性(寄託者記述:日)
使用条件(英)There is no restriction regarding use for basic researches. In relation to commercial use and use for patent filing, first of all please contact the RIKEN BRC.
使用条件(日)基礎的研究につきましては、使用制限はありません。商業利用や特許取得を目的とする場合は、事前に必ず理研細胞バンクに連絡をすること。
備考(英)
備考(日)
提供申込書類(英) Order Form(C-0005.pdf)   MTA(C-0007.pdf)   MTA(C-0007p.pdf)  
Regarding MTA between user institutions and RIKEN BRC, there are two kinds of MTA, not-for-profit academic purpose (C-XXXX) and for-profit research purpose (C-XXXXp) , depending on the sort of user institutions and the purposes of use. Please use an appropriate MTA(to see). In relation to commercial use and use for patent filing, first of all Please contact RIKEN BRC (cellbank.brc@riken.jp).
提供申込書類(日) 依頼書C-0001.pdf   同意書(非営利学術目的)C-0003.pdf   同意書(営利目的)C-0003p.pdf  
提供同意書は、使用機関の種類や目的に応じて、非営利学術目的 (C-XXXX) と営利目的 (C-XXXXp) の2種類があります。該当する提供同意書をご使用ください(詳細)。特許等の取得及び商業利用等は事前に必ず cellbank.brc@riken.jp までご連絡ください。
提供手数料 手数料とお支払いについてはこちらをご覧ください。
細胞基本情報 寄託者 Todoroki, T. & Ohno, T.
樹立者 Todoroki, T. & Ohno, T. & Kim, B.
寄託日 1994
別名 TGBC-2, Na
動物種 _human < Mammals
属名 Homo
種名 sapiens
人種 Japanese
性別 Female
採取組織 gallbladder
転移 Yes
転移巣 lymph node
細胞分類 cancer
初代培養日 1994
細胞寿命 infinite
細胞形態 epithelial-like
Cellosaurus(Expasy) CVCL_3339
細胞培養・検査情報
寄託時情報
ロット情報
培地・試薬情報 培地・試薬一覧はこちらをご覧ください。
培養形態 Adherent cells
培地 DMEM (low glucose) + 5% FBS
抗生物質 Free
継代方法 0.25% Trypsin
継代密度 1 : 4 split
継代・培地交換頻度 Subculture : 1-2 times/week, Medium Renewal : 2 times/week
培養最適温度 37 ℃
二酸化炭素濃度 5 %
凍結培地 Medium + 10% DMSO
凍結方法 Slow freezing
マイコプラズマ/アコレプラズマ (-)
ウィルス(HIV) (-)
ウィルス(HBV) (-)
ウィルス(HCV) (-)
アイソザイム検査 LD, NP
染色体検査 54-59(41) : 54(5),55(7),56(11),57(12),58(5),59(1)
個体識別検査 OK
画像情報
寄託時情報
ロット情報
文献情報 Reference(英) 10件
Reference(日) 4件
利用者成果(英) 47件
利用者成果(日) 0件

トップへページトップへ
Reference(英)
3716  Onuki K1, Sugiyama H, Ishige K, Kawamoto T, Ota T, Ariizumi S, Yamato M, Kadota S, Takeuchi K, Ishikawa A, Onodera M, Onizawa K, Yamamoto M, Miyoshi E, Shoda J.  Expression of N-acetylglucosaminyltransferase V in the subserosal layer correlates with postsurgical survival of pathological tumor stage 2 carcinoma of the gallbladder.  J Gastroenterol  2014  49(4):702-14  PubMed ID: 23588887   DOI: 10.1007/s00535-013-0813-2
2323  Kawashima R, Abei M, Fukuda K, Nakamura K, Murata T, Wakayama M, Seo E, Hasegawa N, Mizuguchi H, Obata Y, Hyodo I, Hamada H, Yokoyama KK.  EpCAM- and EGFR-targeted selective gene therapy for biliary cancers using Z33-fiber-modified adenovirus  Int J Cancer  2011  129(5):1244-53  PubMed ID: 21710497   DOI: 10.1002/ijc.25758
3708  Ishige K, Shoda J, Kawamoto T, Matsuda S, Ueda T, Hyodo I, Ohkohchi N, Puri RK, Kawakami K.  Potent in vitro and in vivo antitumor activity of interleukin-4-conjugated Pseudomonas exotoxin against human biliary tract carcinoma.  Int J Cancer  2008  123(12):2915-22  PubMed ID: 18798553   DOI: 10.1002/ijc.23865
2317  Hori H, Ajiki T, Mita Y, Horiuchi H, Hirata K, Matsumoto T, Morimoto H, Fujita T, Ku Y, Kuroda Y.  Frequent activation of mitogen-activated protein kinase relative to Akt in extrahepatic biliary tract cancer  J Gastroenterol  2007  42(7):567-72  PubMed ID: 17653653   DOI: 10.1007/s00535-007-2055-7
2324  Wakayama M, Abei M, Kawashima R, Seo E, Fukuda K, Ugai H, Murata T, Tanaka N, Hyodo I, Hamada H, Yokoyama KK.  E1A, E1B double-restricted adenovirus with RGD-fiber modification exhibits enhanced oncolysis for CAR-deficient biliary cancers  Clin Cancer Res  2007  13(10):3043-50  PubMed ID: 17505007   DOI: 10.1158/1078-0432.CCR-06-2103
2673  Ghosh, Mila, Koike, Naoto, Yanagimoto, Go, Tsunoda, Shin-Ichi, Kaul, Sunil, Hirano, Takashi, Emura, Fabian, Kashiwagi, Hironobu, Kawamoto, Toru, Ohkohchi, Nobuhiro, Saijo, Kaoru, Ohno, Tadao, Miwa, Masanao, Todoroki, Takeshi  Establishment and characterization of unique human gallbladder cancer cell lines.  Int J Oncol  2004  24:1189-96  PubMed ID: 15067341  
3707  Miyahara N, Shoda J, Kawamoto T, Furukawa M, Ueda T, Todoroki T, Tanaka N, Matsuo K, Yamada Y, Kohno K, Irimura T.  Expression of UDP-N-acetyl-alpha-D-galactosamine-polypeptide N-acetylgalactosaminyltransferase isozyme 3 in the subserosal layer correlates with postsurgical survival of pathological tumor stage 2 carcinoma of the gallbladder.  Clin Cancer Res  2004  10(6):2090-9  PubMed ID: 15041730   DOI: 10.1158/1078-0432.ccr-1024-03
2322  Shoda J, Ueda T, Kawamoto T, Todoroki T, Asano T, Sugimoto Y, Ichikawa A, Maruyama T, Nimura Y, Tanaka N.  Prostaglandin E receptors in bile ducts of hepatolithiasis patients and the pathobiological significance for cholangitis  Clin Gastroenterol Hepatol  2003  1(4):285-96  PubMed ID: 15017670  
3697  Takada M, Ku Y, Habara K, Ajiki T, Suzuki Y, Kuroda Y.  Inhibitory effect of epigallocatechin-3-gallate on growth and invasion in human biliary tract carcinoma cells.  World J Surg  2002  26(6):683-6  PubMed ID: 12053219   DOI: 10.1007/s00268-001-0290-2
2237  Moon,Y., Dahlberg,W. K., Yu,Y., Ohno,T. Todoroki,T., and Little,J. B.   Radiosensitivity of human biliary tract cancer cell lines in vitro  Int J Oncol  1997  10:545-551  PubMed ID: 21533411   DOI: 10.3892/ijo.10.3.545

トップへページトップへ
Reference(日)
2313  小池直人、轟健、川本徹、吉田貞夫、大野忠夫、深尾立、渡辺照男  ヒト胆道癌細胞株と血管内皮との接着に関するE-セレクチンの意義  日本外科学会  1999     
2087  小池直人、轟健、吉田貞夫、川本徹、西條薫、大野忠夫、深尾立、渡辺照男  ヒト胆道癌細胞の浸潤能の評価    1996     
2088  小池直人、轟健、川本徹、西條薫、大野忠夫、深尾立、渡辺照男  ヒト胆道癌細胞株の浸潤能と増殖様式の評価    1996     
2105  小池直人、轟健、川本徹、吉田貞男、大野忠夫、渡辺照男、深尾立  ヒト胆道癌細胞の浸潤能の評価と浸潤に関与するα2インテグリンの意義    1996     

トップへページトップへ
利用者成果(英)
21193  Na L, Masuda S, Nagao S, Morisaki S, Iwamoto N, Sakanashi K, Onishi H.  C4orf47 Contributes to the Induction of Stem-like Properties in Gallbladder Cancer Under Hypoxia.  Anticancer Res  2023  43(5):1925-1932  PubMed ID: 37097647   DOI: 10.21873/anticanres.16352
20194  Ueta E, Tsutsumi K, Kato H, Matsushita H, Shiraha H, Fujii M, Matsumoto K, Horiguchi S, Okada H.  Extracellular vesicle-shuttled miRNAs as a diagnostic and prognostic biomarker and their potential roles in gallbladder cancer patients.  Sci Rep  2021  11(1):12298  PubMed ID: 34112884   DOI: 10.1038/s41598-021-91804-0
16869  Ichimiya S, Onishi H, Nagao S, Koga S, Sakihama K, Nakayama K, Fujimura A, Oyama Y, Imaizumi A, Oda Y, Nakamura M.  GLI2 but not GLI1/GLI3 plays a central role in the induction of malignant phenotype of gallbladder cancer  Oncol Rep  2021  45(3):997-1010  PubMed ID: 33650666   DOI: 10.3892/or.2021.7947
12106  García P, Rosa L, Vargas S, Weber H, Espinoza JA, Suárez F, Romero-Calvo I, Elgueta N, Rivera V, Nervi B, Obreque J, Leal P, Viñuela E, Aguayo G, Muñiz S, Sagredo A, Roa JC, Bizama C.  Hippo-YAP1 Is a Prognosis Marker and Potentially Targetable Pathway in Advanced Gallbladder Cancer.  Cancers (Basel)  2020    PubMed ID: 32218280   DOI: 10.3390/cancers12040778
12131  García P, Bizama C, Rosa L, Espinoza JA, Weber H, Cerda-Infante J, Sánchez M, Montecinos VP, Lorenzo-Bermejo J, Boekstegers F, Dávila-López M, Alfaro F, Leiva-Acevedo C, Parra Z, Romero D, Kato S, Leal P, Lagos M, Roa JC.  Functional and genomic characterization of three novel cell lines derived from a metastatic gallbladder cancer tumor.  Biol. Res.  2020    PubMed ID: 32293552   DOI: 10.1186/s40659-020-00282-7
13185  Pandey A, Stawiski EW, Durinck S, Gowda H, Goldstein LD, Barbhuiya MA, Schröder MS, Sreenivasamurthy SK, Kim SW, Phalke S, Suryamohan K, Lee K, Chakraborty P, Kode V, Shi X, Chatterjee A, Datta K, Khan AA, Subbannayya T, Wang J, Chaudhuri S, Gupta S, Shrivastav BR, Jaiswal BS, Poojary SS, Bhunia S, Garcia P, Bizama C, Rosa L, Kwon W, Kim H, Han Y, Yadav TD, Ramprasad VL, Chaudhuri A, Modrusan Z, Roa JC, Tiwari PK, Jang JY, Seshagiri S.  Integrated genomic analysis reveals mutated ELF3 as a potential gallbladder cancer vaccine candidate.  Nat Commun  2020    PubMed ID: 32839463   DOI: 10.1038/s41467-020-17880-4
20122  Hendaoui I, Lahmar A, Campo L, Mebarki S, Bichet S, Hess D, Degen M, Kchir N, Charrada-Ben Farhat L, Hefaiedh R, Ruiz C, Terracciano LM, Tucker RP, Hendaoui L, Chiquet-Ehrismann R.  Tenascin-W Is a Novel Stromal Marker in Biliary Tract Cancers.  Front Immunol  2020  11:630139  PubMed ID: 33692777   DOI: 10.3389/fimmu.2020.630139
11395  Subbannayya T, Leal-Rojas P, Zhavoronkov A, Ozerov IV, Korzinkin M, Babu N, Radhakrishnan A, Chavan S, Raja R, Pinto SM, Patil AH, Barbhuiya MA, Kumar P, Guerrero-Preston R, Navani S, Tiwari PK, Kumar RV, Prasad TSK, Roa JC, Pandey A, Sidransky D, Gowda H, Izumchenko E, Chatterjee A.  PIM1 kinase promotes gallbladder cancer cell proliferation via inhibition of proline-rich Akt substrate of 40 kDa (PRAS40).  J Cell Commun Signal  2019    PubMed ID: 30666556   DOI: 10.1007/s12079-018-00503-5
3726  Kirti Gondkar, Krishna Patel, Geeta V. Patil Okaly, Bipin Nair, Akhilesh Pandey, Harsha Gowda and Prashant Kumar  Dickkopf Homolog 3 (DKK3) Acts as a Potential Tumor Suppressor in Gallbladder Cancer  Front Oncol  2019  9:1121  PubMed ID: 31737564   DOI: 10.3389/fonc.2019.01121
3738  Yamashita-Kashima Y, Yoshimura Y, Fujimura T, Shu S, Yanagisawa M, Yorozu K, Furugaki K, Higuchi R, Shoda J, Harada N.  Molecular targeting of HER2-overexpressing biliary tract cancer cells with trastuzumab emtansine, an antibody-cytotoxic drug conjugate.  Cancer Chemother Pharmacol.  2019  83(4):659-671  PubMed ID: 30659304   DOI: 10.1007/s00280-019-03768-8
3730  Gamo K, Okuzono Y, Yabuki M, Ochi T, Sugimura K, Sato Y, Sagara M, Hayashi H, Ishimura Y, Nishimoto Y, Murakawa Y, Shiokawa Z, Gotoh M, Miyazaki T, Ebisuno Y.  Gene Signature-Based Approach Identified MEK1/2 as a Potential Target Associated With Relapse After Anti-TNFα Treatment for Crohn's Disease.  Inflamm Bowel Dis  2018  24(6):1251-1265  PubMed ID: 29669006   DOI: 10.1093/ibd/izy079
10170  Weber H, Valbuena JR, Barbhuiya MA, Stein S, Kunkel H, García P, Bizama C, Riquelme I, Espinoza JA, Kurtz SE, Tyner JW, Calderon JF, Corvalán AH, Grez M, Pandey A, Leal-Rojas P, Roa JC.  Small molecule inhibitor screening identifified HSP90 inhibitor 17-AAG as potential therapeutic agent for gallbladder cancer.  Oncotarget  2017  8:26169-26184  PubMed ID: 28412732   DOI: 10.18632/oncotarget.15410
10222  Yang L, Huang S, Ma H, Wu X, Feng F.  MicroRNA-125b predicts clinical outcome and suppressed tumor proliferation and migration in human gallbladder cancer.  Tumour Biol.  2017  39:1010428317692249  PubMed ID: 28347246   DOI: 10.1177/1010428317692249
3690  uchegger K, Silva R2, López J1, Ili C1, Araya JC3, Leal P2, Brebi P1, Riquelme I4, Roa JC5.  The ERK/MAPK pathway is overexpressed and activated in gallbladder cancer.  Pathol Res Pract.  2017  213(5):476-482  PubMed ID: 28285962   DOI: 10.1016/j.prp.2017.01.025
3725  Kawamoto M, Onishi H, Ozono K, Yamasaki A, Imaizumi A, Kamakura S, Nakano K, Oda Y, Sumimoto H, Nakamura M  Tropomyosin-related kinase B mediated signaling contributes to the induction of malignant phenotype of gallbladder cancer.  Oncotarget  2017  8(22):36211-36224  PubMed ID: 28423707   DOI: 10.18632/oncotarget.16063
3727  Yeung Y, Lau DK, Chionh F, Tran H, Tse JWT, Weickhardt AJ, Nikfarjam M, Scott AM, Tebbutt NC, Mariadason JM  K-Ras mutation and amplification status is predictive of resistance and high basal pAKT is predictive of sensitivity to everolimus in biliary tract cancer cell lines.  Mol Oncol  2017  11(9):1130-1142  PubMed ID: 28544747   DOI: 10.1002/1878-0261.12078
3728  Makoto Kawamoto, Hideya Onishi, Keigo Ozono, Akio Yamasaki, Akira Imaizumi and Masafumi Nakamura  TrkB-mediated signaling contributes to malignant phenotypes of gallbladder cancer  Cancer Research  2017  1-5    DOI: 10.1158/1538-7445.AM2017-5794
3731  Mittal B, Yadav S.  Targeting the hedgehog pathway for gallbladder cancer therapy?  Chin Clin Oncol  2016  5(1):2  PubMed ID: 26932426   DOI: 10.3978/j.issn.2304-3865.2015.12.03
3691  Weber H, Leal P, Stein S, Kunkel H, García P, Bizama C, Espinoza JA, Riquelme I, Nervi B, Araya JC, Grez M, Roa JC.  Rapamycin and WYE-354 suppress human gallbladder cancer xenografts in mice.  Oncotarget  2015  6(31):31877-88  PubMed ID: 26397134   DOI: 10.18632/oncotarget.5047
3709  Kawamoto T, Ishige K, Thomas M, Yamashita-Kashima Y, Shu S, Ishikura N, Ariizumi S, Yamamoto M, Kurosaki K, Shoda J.  Overexpression and gene amplification of EGFR, HER2, and HER3 in biliary tract carcinomas, and the possibility for therapy with the HER2-targeting antibody pertuzumab.  J Gastroenterol  2015  50(4):467-79  PubMed ID: 25112701   DOI: 10.1007/s00535-014-0984-5
3729  Subbannayya T et al  Macrophage migration inhibitory factor - a therapeutic target in gallbladder cancer.  BMC Cancer  2015  15:843  PubMed ID: 26530123   DOI: 10.1186/s12885-015-1855-z
17464  Shi Z, Huang Q, Chen J, Yu P, Wang X, Qiu H, Chen Y, Dong Y.  Correlation of HMGB1 expression to progression and poor prognosis of adenocarcinoma and squamous cell/adenosquamous carcinoma of gallbladder  Am J Transl Res  2015  7(10):2015-25  PubMed ID: 26692945  
13739  Letelier P, García P, Leal P, Álvarez H, Ili C, López J, Castillo J, Brebi P, Roa JC.  miR-1 and miR-145 act as tumor suppressor microRNAs in gallbladder cancer  Int J Clin Exp Pathol  2014  7(5):1849-67  PubMed ID: 24966896  
14930  Takahashi N, Aoyama F, Hiyoshi M, Kataoka H, Sawaguchi A.  Establishment and biological characterization of a novel cell line derived from hepatoid adenocarcinoma originated at the ampulla of Vater  Int J Oncol  2014  44(4):1139-45  PubMed ID: 24481592   DOI: 10.3892/ijo.2014.2282
3693  Leal P, Garcia P, Sandoval A, Buchegger K, Weber H, Tapia O, Roa JC.  AKT/mTOR substrate P70S6K is frequently phosphorylated in gallbladder cancer tissue and cell lines.  Onco Targets Ther  2013  6:1373-84  PubMed ID: 24124380   DOI: 10.2147/OTT.S46897
3694  Yang S, Lee KT, Lee JY, Lee JK, Lee KH, Rhee JC.  Inhibition of SCAMP1 suppresses cell migration and invasion in human pancreatic and gallbladder cancer cells.  Tumour Biol  2013  34(5):2731-9  PubMed ID: 23653380   DOI: 10.1007/s13277-013-0825-9
3714  Kato N, Yamamoto H, Adachi Y, Ohashi H, Taniguchi H, Suzuki H, Nakazawa M, Kaneto H, Sasaki S, Imai K, Shinomura Y.  Cancer detection by ubiquitin carboxyl-terminal esterase L1 methylation in pancreatobiliary fluids.  World J Gastroenterol  2013  19(11):1718-27  PubMed ID: 23555160   DOI: 10.3748/wjg.v19.i11.1718
19025  Sekine S, Shimada Y, Nagata T, Moriyama M, Omura T, Yoshioka I, Hori R, Matsui K, Sawada S, Okumura T, Yoshida T, Tsukada K.  Establishment and characterization of a new human gallbladder carcinoma cell line  Anticancer Res  2012  32(8):3211-8  PubMed ID: 22843894  
3722  Ohashi H, Adachi Y, Yamamoto H, Taniguchi H, Nosho K, Suzuki H, Arimura Y, Imai K, Carbone DP, Shinomura Y.  Insulin-like growth factor receptor expression is associated with aggressive phenotypes and has therapeutic activity in biliary tract cancers.  Cancer Sci  2012  103(2):252-61  PubMed ID: 22044563   DOI: 10.1111/j.1349-7006.2011.02138.x
6101  Ono H, Hiraoka N, Lee YS, Woo SM, Lee WJ, Choi IJ, Saito A, Yanagihara K, Kanai Y, Ohnami S, Chiwaki F, Sasaki H, Sakamoto H, Yoshida T, Saeki N.  Prostate stem cell antigen, a presumable organ-dependent tumor suppressor gene, is down-regulated in gallbladder carcinogenesis.  Genes Chromosomes Cancer.  2012  51(1):30-41  PubMed ID: 21936014   DOI: 10.1002/gcc.20928
6319  Wu LC, Chen LT, Tsai YJ, Lin CM, Lin CY, Tian YF, Sheu MJ, Uen YH, Shiue YL, Wang YH, Yang SJ, Wu WR, Li SH, Iwamuro M, Kobayasshi N, Huang HY, Li CF.  Alpha-methylacyl coenzyme A racemase overexpression in gallbladder carcinoma confers an independent prognostic indicator.  J Clin Pathol  2012  65(4):309-14  PubMed ID: 22267983   DOI: 10.1136/jclinpath-2011-200489
16078  Yang MH, Lee KT, Yang S, Lee JK, Lee KH, Moon IH, Rhee JC.  Guggulsterone enhances antitumor activity of gemcitabine in gallbladder cancer cells through suppression of NF-κB  J Cancer Res Clin Oncol   2012  138(10):1743-51  PubMed ID: 22699931   DOI: 10.1007/s00432-012-1254-7
7862  Sato J, Kimura T, Saito T, Anazawa T, Kenjo A, Sato Y, Tsuchiya T, Gotoh M.  Gene expression analysis for predicting gemcitabine resistance in human cholangiocarcinoma.  J Hepatobiliary Pancreat Sci  2011  18:700-11  PubMed ID: 21451941   DOI: 10.1007/s00534-011-0376-7
19029  Kanamori-Katayama M, Kaiho A, Ishizu Y, Okamura-Oho Y, Hino O, Abe M, Kishimoto T, Sekihara H, Nakamura Y, Suzuki H, Forrest AR, Hayashizaki Y.  LRRN4 and UPK3B are markers of primary mesothelial cells  PLoS One  2011  6(10):e25391  PubMed ID: 21984916   DOI: 10.1371/journal.pone.0025391
3711  Fukushima T, Kawaguchi M, Yamasaki M, Tanaka H, Yorita K, Kataoka H.  Hepatocyte growth factor activator inhibitor type 1 suppresses metastatic pulmonary colonization of pancreatic carcinoma cells.  Cancer Sci  2011  102(2):407-13  PubMed ID: 21166957   DOI: 10.1111/j.1349-7006.2010.01808.x
8464  Yamaguchi J, Sasaki M, Sato Y, Itatsu K, Harada K, Zen Y, Ikeda H, Nimura Y, Nagino M, Nakanuma Y.  Histone deacetylase inhibitor (SAHA) and repression of EZH2 synergistically inhibit proliferation of gallbladder carcinoma.  Cancer Sci.  2010  101:355-62  PubMed ID: 19860841   DOI: 10.1111/j.1349-7006.2009.01387.x
8548  Yamaguchi J, Sasaki M, Harada K, Zen Y, Sato Y, Ikeda H, Itatsu K, Yokoyama Y, Ando H, Ohta T, Kubota A, Shimizu K, Nimura Y, Nagino M, Nakanuma Y.  Papillary hyperplasia of the gallbladder in pancreaticobiliary maljunction represents a senescence-related lesion induced by lysolecithin.  Lab. Invest.  2009  89:1018-31  PubMed ID: 19564843   DOI: 10.1038/labinvest.2009.65
3705  Oka T, Yamamoto H, Sasaki S, Ii M, Hizaki K, Taniguchi H, Adachi Y, Imai K, Shinomura Y.  Overexpression of beta3/gamma2 chains of laminin-5 and MMP7 in biliary cancer.  World J Gastroenterol  2009  15(31):3865-73  PubMed ID: 19701966   DOI: 10.3748/wjg.15.3865
18693  Shibata T, Kokubu A, Gotoh M, Ojima H, Ohta T, Yamamoto M, Hirohashi S.  Genetic alteration of Keap1 confers constitutive Nrf2 activation and resistance to chemotherapy in gallbladder cancer  Gastroenterology  2008  135(4):1358-1368  PubMed ID: 18692501   DOI: 10.1053/j.gastro.2008.06.082
3712  Maehata T, Taniguchi H, Yamamoto H, Nosho K, Adachi Y, Miyamoto N, Miyamoto C, Akutsu N, Yamaoka S, Itoh F.  Transcriptional silencing of Dickkopf gene family by CpG island hypermethylation in human gastrointestinal cancer.  World J Gastroenterol  2008  14(17):2702-14  PubMed ID: 18461655   DOI: 10.3748/wjg.14.2702
19308  Taniguchi H, Yamamoto H, Akutsu N, Nosho K, Adachi Y, Imai K, Shinomura Y.  Transcriptional silencing of hedgehog-interacting protein by CpG hypermethylation and chromatic structure in human gastrointestinal cancer  J Pathol  2007  213(2):131-9  PubMed ID: 17724792   DOI: 10.1002/path.2216
19219  Sato K, Kitajima Y, Koga Y, Miyazaki K.  The effect of o6-methylguanine-DNA methyltransferase (MGMT) and mismatch repair gene (hMLH1) status on the sensitivity to alkylating agent 1-(4-amino-2-methyl-5-pyrimidinyl)methyl-3-(2-chloroethyl)-3-nitrosourea(ACNU) in gallbladder carcinoma cells  Anticancer Res  2005  25(6B):4021-8  PubMed ID: 16309194  
3701  DINGAng TONGSaixiong SUOTao  Relations of hTERT and β-Catenin Expression with Cell Growth and Invasion in Gallbladder Cell Line  Clinical Medical Journal of China  2005     
3713  Taniguchi H, Yamamoto H, Hirata T, Miyamoto N, Oki M, Nosho K, Adachi Y, Endo T, Imai K, Shinomura Y.  Frequent epigenetic inactivation of Wnt inhibitory factor-1 in human gastrointestinal cancers.  Oncogene  2005  24(53):7946-52  PubMed ID: 16007117   DOI: 10.1038/sj.onc.1208910
13744  Sato K, Kitajima Y, Kohya N, Miyoshi A, Koga Y, Miyazaki K.  Deficient MGMT and proficient hMLH1 expression renders gallbladder carcinoma cells sensitive to alkylating agents through G2-M cell cycle arrest  Int J Oncol  2005  26(6):1653-61  PubMed ID: 15870882  
3717  Wada M, Yazumi S, Takaishi S, Hasegawa K, Sawada M, Tanaka H, Ida H, Sakakura C, Ito K, Ito Y, Chiba T.  Frequent loss of RUNX3 gene expression in human bile duct and pancreatic cancer cell lines.  Oncogene  2004  23(13):2401-7  PubMed ID: 14743205   DOI: 10.1038/sj.onc.1207395
3699  Nakano K, Todo T, Chijiiwa K, Tanaka M.  Therapeutic efficacy of G207, a conditionally replicating herpes simplex virus type 1 mutant, for gallbladder carcinoma in immunocompetent hamsters.  Mol Ther  2001  3(4):431-7.  PubMed ID: 11319903   DOI: 10.1006/mthe.2001.0303

トップへページトップへ
利用者成果(日)



戻る 戻る 理研トップページへ